| DIRECT COMPETITOR COMPARISON | |
| THLD | LLY | PFE | Industry | | Market Cap: | 61.42M | 41.46B | 150.09B | 104.49M | | Employees: | 30 | 40,500 | 81,800 | 68 | | Qtrly Rev Growth (yoy): | N/A | 6.80% | -2.90% | 19.10% | | Revenue (ttm): | 360.00K | 21.11B | 45.82B | 13.84M | | Gross Margin (ttm): | 100.00% | 82.33% | 86.61% | 64.07% | | EBITDA (ttm): | -19.98M | 7.74B | 21.31B | -11.86M | | Oper Margins (ttm): | -5,752.22% | 30.97% | 37.42% | -149.46% | | Net Income (ttm): | -23.71M | -216.00M | 8.09B | N/A | | EPS (ttm): | -1.556 | -0.197 | 1.204 | -0.33 | | P/E (ttm): | N/A | N/A | 15.45 | 17.48 | | PEG (5 yr expected): | N/A | 6.28 | 5.99 | 1.35 | | P/S (ttm): | 173.40 | 1.96 | 3.27 | 10.13 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.42 | 0.12% | 58.12B | 12.52 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 52.24 | 0.15% | 15.11B | 17.48 | | Genzyme Corp. | GENZ | 48.50 | 0.62% | 12.87B | 27.65 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.00 | -0.02% | 38.70B | 16.63 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.17 | 0.68% | 9.30B | 1064.69 | | Teva Pharmaceutical Industries Limited | TEVA | 55.94 | -0.07% | 49.28B | 51.18 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.91 | 0.28% | 4.24B | 20.57 | | King Pharmaceuticals Inc. | KG | 12.14 | -0.82% | 3.01B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.74 | 0.00% | 5.73B | 114.97 | | Pfizer Inc. | PFE | 18.60 | 0.11% | 150.09B | 15.45 | | Johnson & Johnson | JNJ | 64.70 | 0.20% | 178.51B | 14.13 | | GlaxoSmithKline plc | GSK | 42.29 | 0.48% | 107.21B | 13.87 | | Sanofi-Aventis | SNY | 39.87 | 0.43% | 104.11B | N/A | | Novartis AG | NVS | 54.84 | 0.44% | 124.55B | 16.42 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.20 | 0.93% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 0.89% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.15 | 0.11% | 83.76B | 14.67 | | Bristol-Myers Squibb Co. | BMY | 25.76 | 0.23% | 51.03B | 13.33 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | LLY | | [$$] Dwindling Options at Take-Two
Sat 2:17pm -
at Barrons.com | | • | PFE | | Jim Cramer's Portfolios of the Week
Fri, Dec 25 -
at TheStreet.com | | • | PFE | | Matthew Herper And Robert Langreth On The Pharmaceutical Industry
Thu, Dec 24 -
at Forbes.com | | • | PFE | | Merry Job News Sends Stocks Higher
Thu, Dec 24 -
Indie Research | | • | PFE | | Many Reasons to Launch a Global Generic Drug ETF
Thu, Dec 24 -
at Seeking Alpha | | • | PFE | | SEC: Men Made 'Illicit Profits' in Sanofi-Chattem Deal
Thu, Dec 24 -
at The Wall Street Journal Online | | • | PFE | | [$$] Medicines Co.'s Lackluster Pfizer Deal
Thu, Dec 24 -
at Barrons.com | | • | PFE | | Dividend Stocks for the Week
Thu, Dec 24 -
at TheStreet.com | | • | LLY | | Another Reason to Worry About Pfizer
Thu, Dec 24 -
at Motley Fool | | • | LLY | | Pfizer Expands Chinese Presence
Thu, Dec 24 -
Zacks.com | | • | LLY | | Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
Thu, Dec 24 -
at Seeking Alpha | | • | LLY | | Pharma Spreads Holiday Cheer in Bevy of Biotech Deals
Thu, Dec 24 -
at Seeking Alpha | | • | LLY | | UPDATE - Amylin shares drop after FDA requests new studies
Wed, Dec 23 -
at Reuters | | • | LLY | | Eli Lilly, Kowa Partner to Market Cholesterol Drug Livalor in U.S.
Wed, Dec 23 -
at Fox Business | | • | LLY | | Novartis Partnership And International Sales Position Cubist Pharmaceuticals As A Good Investment, According To Former Vice President Of Morgan Stanley
Wed, Dec 23 -
Wall Street Transcript | | | All Headlines for these symbols... |
|
|
|
0.51% Nasdaq 
0.03 (1.61%) 
Competitors
